Change of lipoprotein(a) and coagulative or fibrinolytic parameters in diabetic patients with nephropathy.
Nagai
T
T
Tomizawa
T
T
Mori
M
M
D000419:Albuminuria; D000933:Antifibrinolytic Agents / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000652:urine; D003928:Diabetic Nephropathies / Q000097:blood* / Q000652:urine; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D010314:Partial Thromboplastin Time; D010447:Peptide Hydrolases / Q000032:analysis; D011517:Prothrombin Time; D012016:Reference Values; D000979:alpha-2-Antiplasmin
D000933:Antifibrinolytic Agents; D017270:Lipoprotein(a); D008074:Lipoproteins; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin